Ad hoc announcement pursuant to Art. 53 LR...
Conference call scheduled for Thursday, July 28, 2022, at 8 AM EDTÂ /Â 2 PM CET...
ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its...
ALLSCHWIL, Switzerland, May 19, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX) today announced that the company will present at the H.C. Wainwright...
ALLSHWIL, SWITZERLAND / ACCESSWIRE / May 12, 2022 / Spexis AG (SIX: SPEX) today announced that that the company will present at BioEquity Europe, taking place May 17 & 18, 2022. Jeff Wager, CEO of Spexis,...
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, SWITZERLAND / ACCESSWIRE / April 27, 2022 / Spexis AG (SIX:SPEX) today announced that its shareholders approved all proposals of the Board of Directors...
Ad hoc announcement pursuant to Art. 53 LR - Pre-AGM information call on April 7, 2022 at 2:30PM CET - AGM to be held April 26, 2022 - Shareholders not physically present, in accordance with COVID-19 ordinances...
- Successful launch of Spexis AG as a reverse merger of Polyphor AG with EnBiotix Inc. - Successful closing of a USD 12.8 million pre-merger financing - First patient enrollment and start of Phase 1 trial...
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, SWITZERLAND / ACCESSWIRE / March 9, 2022 / Spexis AG (SIX:SPEX) announced today that it will publish its full-year financial results for 2021 on March...
ALLSCHWIL, SWITZERLAND / ACCESSWIRE / March 3, 2022 / Spexis AG (SIX:SPEX) announced today that it has been awarded the second part of its phased funding grant from CARB-X (Combating Antibiotic-Resistant...